Amyris Inc (NASDAQ:AMRS) Posts Another Remarkable Quarter


Amyris Inc (NASDAQ:AMRS) posted preliminary unaudited financial report for the fourth quarter closed December 31, 2017. GAAP revenue for Q4 2017 came at $80.6 million versus $22.2 million for Q4 2016. The firm recognized license and royalty revenues of approximately $57.3 million from the value share and multi-element license deal with DSM. Hence, license and royalty revenues led to $57.7 million and recorded an increase of $0.3 million from Q4 2016. Product sales came at $13.4 million for Q4 2017 versus $11.2 million for Q4 2016.

The buzz

John Melo, the CEO and President of Amyris, expressed that they have closed another record year and an extremely robust fourth quarter. They have surpassed their major targets for 2017 and have begun 2018 with sustained strong growth in operating performance and revenues. They are done with the transformation of their firm into one of the major international firms emphasized on making their planet healthier.

The company has organized around three major markets, Performance Health and Wellness, Pure Flavor and Fragrance Ingredients, and Clean Skin-Care. Each of these segments is offering strong, profitable growth supported by the most benefitted technology in the segment. They are making better for humanity and their planet with No Compromise® offerings. Melo expressed that they are extremely delighted with their performance and anticipate another extremely robust year offering continued market disruption with their associates.

Other key developments and operating highlights during Q4 2017 and more recently comprised expanded strategic association with DSM via the sale of Amyris Brasil Ltda. and set long-term manufacturing association for Amyris’s high-volume offerings; successfully introduced Biossance into SEPHORA Canada outlets, with SEPHORA U.S. sales during 2071 overall contributing to over 650% jump in aggregate 2017 Biossance retail sales in 2016. Amyris launched Neossance® Squalane USP via their Aprinnova joint venture introducing new segments among FDA regulated offerings such as dermal and topical applications.